Clinical Trial

Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multicenter，randomized, open label, active-controlled, parallel-group study comparing efficacy and safety of LY01610(Irinotecan hydrochloride liposome Injection) and Topotecan in Patients with Recurrent Small Cell Lung Cancer (SCLC)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-11-07.
Status change: Not Yet Recruiting → Recruiting 2024-03-12
Trial Details
NCT Number NCT06128837
Lead Sponsor Luye Pharma Group Ltd.
Conditions Relapsed Small Cell Lung Cancer
Enrollment 686 participants
Start Date 2024-03-03
Primary Completion 2028-06 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2024-03-15